Vir Biotechnology raises $150M in stock offering ahead of key trials
What's the deal? Vir Biotechnology priced a public offering of 15 million shares at $10 each, raising $150 million in gross proceeds. The clinical-stage biopharmaceutical company, listed on Nasdaq as VIR, expects the offering to close on November 16, 2026.
The terms: All shares are being sold by Vir. It also granted underwriters a 30-day option to buy up to 2.25 million additional shares at the offering price. Leerink PartnersDealroom has a profile for this one. Try Dealroom →, Morgan Stanley, and Evercore ISI led the deal, with Raymond James as co-manager.
What's the endgame? Vir develops medicines for serious infectious diseases and cancer. Proceeds will fund pre-commercial work on its chronic hepatitis delta program and its T-cell engager oncology platform. Phase 3 hepatitis delta results are expected in late 2026 and early 2027.
Why now? The raise is Vir's second $150 million stock offering in 2026, following a February sale at $8.50 a share. It comes despite a healthy balance sheet: $901 million in cash and investments at September 30, plus a $90 million upfront payment from Gilead in October.
The company has said its existing resources would fund operations into the second half of 2028. The new sale appears to bolster funding ahead of clinical milestones rather than address a shortfall.
What could go wrong? The offering dilutes existing shareholders. Vir priced the shares at $10, below its November 11 Nasdaq close of $13.13 — a discount new investors are being asked to accept to fund a clinical-stage pipeline.
The signal: Biotechs are tapping public markets to stockpile cash ahead of pivotal readouts, even when balance sheets look comfortable. For Vir, raising now locks in capital before late-stage trial data that could move the stock either way.
Read more: business.theantlersamerican.com
Image credit: Generated with Gemini